



# Too young to compete?

## Relevance to genes and other considerations

Prof. Dr. Hein Heidbuchel, MD PhD

Cardiology - Electrophysiology  
University Hospital Gasthuisberg, University of Leuven, Belgium



# Overview

- Genotyping children/adolescents in the context of pre-participation screening
  1. medical considerations
  2. ethical considerations
- Exercise and the developing heart
  3. long-term concerns



# Screening in practice

## ESC/IOC Recommendation

---

- Basic screening
  - Personal and familial history
  - Physical examination
  - Resting 12-lead ECG
  - Genetic evaluation
    - in those with suspected phenotype or familial presence
    - in all... ?
      - high throughput sequencers > whole genome scanning
      - at a reasonable cost
      - direct-to-customer testing...



KU Leuven

# European Sports Cardiology Recommendations



Channelopathies and familial cardiomyopathy:  
List of recommendations, mostly restrictions.  
"Similar for asymptomatic mutation carriers"

# Center for Hereditary Heart Diseases, Leuven

Centrum voor Erfelijke Hartziekten



Centrum Erfelijke Hartziekten

Dienst  
Cardiologie

Dienst  
Kindercardiologie

Centr. Menselijke  
Erfelijkheid

Aritmieën

Cardio-  
myopathieën

Aritmieën

Cardio-  
myopathieën

Klinische  
Genetica

Psychosociale  
Genetica

Laboratorium  
Moleculaire  
Diagnostiek

Dr. T. Rossenbacker  
Dr. R. Willems  
Prof. Dr. H. Heidbüchel

Prof. Dr. J. Van Cleemput

Prof. Dr. M. Gewillig

Prof. Dr. L. Mertens







Dr. T. de Ravel

Prof. Dr. K. Devriendt

Prof. Dr. G. Evers-Kiebooms

Lab.Assist. C. Kuiperi  
Ing. E. Schollen  
Prof. Dr. G. Matthijs

# Genetic evaluation: multiple candidate genes - multiple mutations





# Medical considerations

## 1. Is the genetic variant really a mutation?

- not a problem for truncated proteins
- uncertain for many missense mutations
  - population prevalence
  - comparison with other species
  - protein modeling
  - family co-segregation studies
  - in vitro functional evaluation
    - channelopathies: OK
    - cardiomyopathies: much more difficult
- SNP: increasing vulnerability...



# Medical considerations

## 2. Genotyping as a diagnostic test

- genetic evaluation cannot exclude diagnosis
  - unknown genes
  - interactions with other genes and environmental modifiers
- even if positive genotype: no certitude about phenotype
  - non-penetrance
  - variable expression
- i.e.: no substitute for phenotyping
  - but is difficult to interpret in adolescents



# Medical considerations

## 3. Genotyping as a prognostic test

- i.e.: risk-stratification dependent on genotype
  - “genotype-phenotype correlations”

e.g. risk-stratification LQTS based on QTc/gender/type<sup>1</sup>

- not waterproof
- restrict sport to LQT1 and -2 carriers, but not to LQT3?<sup>2</sup>
- advice concerning type of sport: swimming, diving, ... vs other?<sup>2</sup>

1. Priori et al, N Eng J Med 2003;

2. Heidbuchel et al, for the Section on Sports Cardiology, EJCPR 2006



# Medical considerations

## 4. Genotyping as a predictive test

- Meaningfulness depends on:
  1. **Degree of certainty** in predicting disease + outcome
    - Non-penetrance and variable expression...
  2. Availability of **preventive measures** that affect outcome
    - How much will sports restriction affect outcome?
    - And does this apply in the same way to children as to adults?
- Clinical arena is a wide spectrum...



# Ethical considerations

## 1. Informed consent

- how much information?
- formally: if  $<18y$ : parents give consent
  - but child has its rights to have partaking in decision ! <sup>1</sup>
  - therefore:
    - no testing for diseases starting in adulthood, or
    - testing few years before disease may become manifest
- “free consent”
  - pressure of family / parents
  - official screening programs



# Ethical considerations

## 2. Privacy

- consensus not to pass genetic information to others
  - team physician  $\neq$  treating physician
  - team manager, authorities, ...
  - but restricting sports = passing information
- rule: patient informs those that he wants to inform



# Ethical considerations

## 3. The patient has the right NOT to know

- even after information has been gathered
- but can get in conflict with right of others to know...
  - child wants to know vs. parent does not want:
    - who has priority... ?
    - no clear ethical consensus; depends on individual circumstances.



# Ethical considerations

## 4. Non-directivity

- advice may not steer towards particular decision.
- could a fortiori be applied to all screening findings...
- balance between
  - right of patient to decide freely
  - and
  - perceived freedom of patient to decide (e.g. competitive athletes)



# Ethical considerations

## 5. High-throughput sequencing

- how to deal with **unclassified variants**?
- how to deal with **incidental findings**?
- **genome** made available for study
  - but tells who you are: not anonymous!
  - and tells 50% of what your family members are
  - no minors in biobanks unless personal medical benefit is likely.



# "Sports injuries in young athletes are a public health issue"<sup>1</sup>

- Related to increased intensity and volume:
  1. **acute** injuries
  2. **overuse** injuries
    - some specifically associated with children and adolescents
    - particularly vulnerable because processes of growth
  3. **long-term** medical impact (e.g. osteoarthritis)
    - under-investigated so far..., fruitful area for future research.



# After a marathon, triathlon or other endurance event

- Increases in CK-MB, cTnT, cTnI in 40-57%<sup>6-12</sup>
- LV: rarely dysfunction<sup>2-4,6,7</sup>
- RV: dilatation and hypokinesia in  $\pm 30\%$ <sup>1,5,6,7</sup> to 100%<sup>13</sup>



# RV morphological changes

## Acute > Chronic ?


- Hypothesis:
  - Repeated RV insults may result in long-term RV dysfunction
  - There may be a limit to what is healthy for the RV...
- Facilitating factors?
  1. Performance enhancing drugs?
  2. Genetic predisposition?
  3. Other ... ?

1. Heidbuchel et al, Eur Heart J 2003; 2. Ector & Heidbuchel, Eur Heart J 2007;  
3. La Gerche et al, Heart 2008; 4. La Gerche, Heidbuchel & Priori, ESC 2009

# Desmathlete trial

## Mutation findings in 47 athletes with "ARVC"

- 9 different heterozygous desmosomal sequence variants in 10 patients
  - 7 novel - 2 previously known
  - 5 (in 6 patients, 12.8%) manifestly pathogenic



LaGerche & Heidbuchel, Heart 2010 (in press)


\*: 1. Sen-Chowdhry et al, Circ 2007; 2. Dalal et al, Circ 2006; 3. Gerull et al, Nature Genetics 2004; 4. Pilichou et al, Circ 2006; 5. van Tintelen et al, Circ 2006; 6. den Haan et al, Circ Cardiovasc Genetics 2009; 7. Sen-Chowdhry et al, JACC 2007



# Desmathlete trial

## genotype vs. phenotype vs. exercise level

- Athletes without a desmosomal mutation performed more exercise
  - $14.3 \pm 8.9$  vs.  $9.2 \pm 2.3$ ,  $p=0.005$
- No athlete performing above average exercise had a mutation.





# "Sports injuries in young athletes are a public health issue"<sup>1</sup>

- Needed:
  - awareness (of athletes, trainers, therapists, scientists)
  - prevention programmes (and their evaluation)
    - including passive prevention:
      - protective equipment,
      - rules, ...

# Youth Olympic Games

## Promotion of sports because it's healthy?



Too young to compete?  
even if we thoroughly screen them  
phenotypically,  
psychologically,  
or genotypically...